Friday, March 11, 2016 at 10:45AM


 The AHCI is delighted to announce its participation in the funding of $125,000 for the second half of the research project “Molecular Physiology and Pharmacology of ATP1A3 Mutations in AHC” being carried out at Vanderbilt University School of Medicine under the direction of Dr. Kevin Ess and Northwestern University, Chicago under the direction of Dr. Alfred George.    The funding was in part provided by the Alternating Hemiplegia of Childhood Foundation (AHCF) in the US to the amount of $120,000 and $5,000 by the AHCI.  

Dr Ess stated, "The very generous donation by the AHCF and AHCI will enable us to determine mechanisms used by specific ATP1A3 mutations that cause AHC. Our experiential approach was designed to most quickly identify disease pathways as well as potential therapeutics that can help those afflicted with AHC.”

 “This is where the research gets really exciting!  Work is finally being done on potential drug treatments for our kids.” Said AHCF President Lynn Egan.

"We are delighted to be in a position to make our first donation to a research project that is actively looking for a treatment for our kids. This was one of the key reasons the AHCI was founded in the first place - to fund and drive research.  We would also like to thank the AHCF and particulary Lynn Egan for allowing us to participate in this research project and we would like to wish both the teams in Vanderbilt and Northwestern all the very best with their research.  Finally, we would like to thank those who made this donation possible, the parents, donors and fundraisers of the AHCI" Chairman AHCI Tom O'Brien


Article originally appeared on AHCI - Alternating Hemiplegia Childhood Ireland (http://www.ahci.ie/).
See website for complete article licensing information.